Skip to content
Evigrade
CriticalPharmacokinetic enhancer (booster) for antiretroviral therapy×Class III antiarrhythmic

Updated · Methodology

Mechanism

CYP3A4 is the main enzyme that metabolises dronedarone, so inhibitors of this enzyme raise its levels. The strong inhibitor ketoconazole increased dronedarone levels 17-fold (dronedarone summary of product characteristics, SmPC, European Medicines Agency, EMA). Cobicistat is a strong CYP3A inhibitor used to boost atazanavir or darunavir, and it raises the levels of drugs metabolised by CYP3A (cobicistat SmPC, EMA). The interaction table of the US cobicistat label shows increased dronedarone levels (cobicistat label, US Food and Drug Administration, FDA). Dronedarone prolongs the QT interval on the electrocardiogram, and the higher its concentration, the longer the QT (dronedarone FDA label). The reverse effect is also possible: dronedarone moderately inhibits CYP3A4, and CYP3A inhibitors slow the clearance of cobicistat and raise its levels (dronedarone and cobicistat SmPCs, EMA).

Symptoms

Higher dronedarone levels carry a risk of serious, including life-threatening, reactions such as cardiac arrhythmias (cobicistat label, US Food and Drug Administration, FDA). Dronedarone prolongs the QT interval on the electrocardiogram (ECG), and it is stopped if the Bazett-corrected QTc reaches 500 milliseconds or more (dronedarone summary of product characteristics, European Medicines Agency, EMA). QT prolongation itself causes no symptoms and shows only on the ECG.

Management

The combination is contraindicated. The US cobicistat label lists dronedarone among its contraindications without conditions because of the risk of serious and life-threatening reactions such as cardiac arrhythmias (cobicistat label, US Food and Drug Administration, FDA). In Europe, dronedarone is contraindicated by name with the tablets that combine cobicistat with darunavir or atazanavir (darunavir/cobicistat and atazanavir/cobicistat summaries of product characteristics, SmPCs, European Medicines Agency, EMA). The EU SmPC of cobicistat itself does not name dronedarone. It contraindicates drugs that depend heavily on CYP3A for clearance and whose high levels are linked to serious or life-threatening reactions (cobicistat SmPC, EMA). The dronedarone SmPC and label contraindicate strong CYP3A4 inhibitors and name ritonavir, the other booster of the same drugs. Cobicistat is not on that list, although its own SmPC describes it as a strong CYP3A inhibitor (dronedarone SmPC, EMA, and FDA label; cobicistat SmPC, EMA). Before starting cobicistat and during treatment, consider possible interactions, review all concomitant medicines and monitor for their adverse effects (cobicistat FDA label). In dronedarone overdose, monitor heart rhythm and blood pressure and give supportive, symptom-based treatment. There is no specific antidote, and it is not known whether dialysis removes dronedarone (dronedarone SmPC, EMA). Correct low potassium or magnesium before starting dronedarone and during treatment. Stop dronedarone if the QTc interval on the electrocardiogram reaches 500 milliseconds or more (dronedarone SmPC, EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Cobicistat

Other interactions with Dronedarone